NBS

Neostem, Inc. Press Releases

$3.29
*  
0.10
2.95%
Get NBS Alerts
*Delayed - data as of Dec. 18, 2014 12:12 ET  -  Find a broker to begin trading NBS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    NBS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference
12/15/2014 7:30:00 AM - GlobeNewswire


NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ Manufacturing Facility
12/8/2014 7:30:00 AM - GlobeNewswire


"New To The Street"Announces Nationwide Broadcast
12/3/2014 9:30:00 AM - Market Wire
▼-15.86 % Price Change since this news event. The Volume Ratio is 0.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences
12/1/2014 7:30:00 AM - GlobeNewswire


Fifth Street Finance Corp. Declares Consistent Monthly Dividend of 9.17 Cents Per Share
11/26/2014 7:30:00 AM - GlobeNewswire


NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014
11/26/2014 7:30:00 AM - GlobeNewswire


NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine
11/25/2014 7:30:00 AM - GlobeNewswire


NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial
11/21/2014 3:08:00 PM - GlobeNewswire


NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial
11/17/2014 5:15:00 PM - GlobeNewswire


NeoStem to Present at Multiple November Conferences
11/12/2014 7:30:00 AM - GlobeNewswire


NeoStem Data From Phase 2 PreSERVE AMI Clinical Trial to be Presented at American Heart Association Scientific Sessions on November 17
11/10/2014 7:30:00 AM - GlobeNewswire


NeoStem Announces Additions to Management
11/5/2014 7:30:00 AM - GlobeNewswire


NeoStem to Present at Multiple Conferences This Week
11/3/2014 7:30:00 AM - GlobeNewswire


NeoStem Announces Third Quarter 2014 Financial Results and Outlines Near Term Milestones
10/30/2014 4:14:00 PM - GlobeNewswire


NeoStem Announces BioProcess International Excellence in Leadership Award Given to Dr. Robert Preti, Chief Scientific Officer and President of PCT
10/27/2014 7:30:00 AM - GlobeNewswire


BioLife Solutions Biopreservation Media Products Used at NeoStem Subsidiary Progenitor Cell Therapy
10/14/2014 6:00:00 AM - PR Newswire


NeoStem Ranked as One of the Fastest Growing Companies in New York City
10/13/2014 7:30:00 AM - GlobeNewswire


NeoStem Announces USAN Approval of Generic Name 'Eltrapuldencel-T' for Investigational Patient-Specific Targeted Cancer Immunotherapy
10/6/2014 7:30:00 AM - GlobeNewswire


NeoStem to Present at Multiple October Conferences
10/2/2014 4:30:00 PM - GlobeNewswire


NeoStem Establishes Melanoma Scientific Advisory Board to Support Anticipated Phase 3 Trial
10/1/2014 7:30:00 AM - GlobeNewswire


NeoStem Secures Debt Facility
9/29/2014 7:30:00 AM - GlobeNewswire